Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
about
Brief History and Characterization of Enhanced Respiratory Syncytial Virus DiseaseStructure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing EpitopesAnalysis of Human RSV Immunity at the Molecular Level: Learning from the Past and PresentImmunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in miceA peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatmentEvasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model.Immune responses and disease enhancement during respiratory syncytial virus infectionRespiratory syncytial virus vaccinesProphylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.Immunity to RSV in Early-Life.Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cellsIdentification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells.Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf).Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractGeneration of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV.Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins.Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.Novel antigens for RSV vaccines.A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton ratsCharacteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of AgeVenezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BAn Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold.Viral and host factors in human respiratory syncytial virus pathogenesis.Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cellsRespiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.Current approaches to the development of vaccines effective against parainfluenza viruses.Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.
P2860
Q26775152-B15F35F0-0BD8-4E94-8ED4-FB8D3DCA6A8BQ27668015-15F8C93D-4FDD-4A32-A045-83C496D499ADQ28080556-1513BE4D-EFD4-4BE3-A5A4-BD3631FA3E10Q28730052-86CE133A-8379-4FAB-8D54-55E046552211Q32099239-E718CAFA-5A26-479F-BFAB-64175960C56BQ33177627-069381E4-239F-42C1-AD2E-B066F835F266Q33588916-1BC76BFE-9D37-4CB4-A836-F0A77040F90AQ33756740-D4381911-1A32-43A9-9C8E-066652023AF9Q33840469-7508427F-1FEE-4650-97ED-27947F466CBAQ33887642-103F3AB1-DF6C-44FE-A768-8DDFB8522A13Q33937152-4A2C338A-4720-4C00-BC16-1F8B2BCA63F0Q33975330-E060D3E2-5954-4F44-957F-CDA918F5AD5EQ34120278-07B20F4A-3215-4211-B336-379408F5F95EQ34264615-CB06E7B7-5FC5-4D65-9BD8-E3E7FD3E2435Q34326260-C0FBEDFD-8772-4304-B39D-A5D4F0FD8F9AQ34465367-B5B1A34D-0BD1-4717-8233-AC75B82D2D64Q34504791-4F75F54B-64BC-4407-B2BF-8CB6D87127B7Q35149594-859F03B9-A810-4A8E-836E-DD44B2C9FA43Q35667184-04F44FD6-B562-47B1-B468-10165360DA71Q35690781-C037A393-1517-421A-A0B4-62FFBA0EC546Q35872191-62282C7D-E075-47D9-95AA-548834499A4EQ35892441-B157CD74-6FCA-45A0-A443-E506C91CAC61Q35914345-1BF47BAC-6DC8-4FD3-8222-16E431182A8BQ35995788-2EB7E345-F29C-4A63-9510-B0368400EDF9Q36005114-FA17EDED-6240-4837-8954-F4F19555783DQ36005960-345ACFBA-04D6-471B-B9A8-A5D343CB6AC9Q36251566-2ABCA0FD-580F-486A-946A-FC014E9E6061Q36263882-6036BB72-6B73-4E7C-9D1E-6D0291D9431DQ36315159-DB49D7E9-30E7-4331-8174-43AAF356B429Q36453608-470DE889-ACED-4FDA-9C76-DF0914C41630Q36469725-08BE96F4-EA29-4820-BA70-EBDC65533789Q36483836-5EA9707B-FB32-4355-A2F4-3A43B31E3023Q36626174-7B90BAE6-1C09-433F-BED4-4754EF0CF366Q36687435-39784FE1-1BAE-48AE-9C23-3A2B3C00FB8FQ36692791-1F8B86DB-B658-433F-AABD-75AA0A98A59AQ36799591-84937B0F-1D09-4CCD-9C64-87A07E76EAE2Q36873249-197D85D6-F4A1-45F3-8454-D35EB0B8B91EQ36919535-79A34415-4C9D-415B-8B37-310C62ACBEB4Q36920250-091DBD75-17EB-4E52-AE52-52BD24DEFB01Q36922491-CD4C93C9-3805-4842-AA2A-A18F67ED2B29
P2860
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1986
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dissociation between serum neu ...... atory syncytial virus vaccine.
@en
Dissociation between serum neu ...... atory syncytial virus vaccine.
@nl
type
label
Dissociation between serum neu ...... atory syncytial virus vaccine.
@en
Dissociation between serum neu ...... atory syncytial virus vaccine.
@nl
prefLabel
Dissociation between serum neu ...... atory syncytial virus vaccine.
@en
Dissociation between serum neu ...... atory syncytial virus vaccine.
@nl
P2093
P2860
P1476
Dissociation between serum neu ...... atory syncytial virus vaccine.
@en
P2093
Chanock RM
Hemming VG
Parrott RH
Rodriguez WJ
P2860
P304
P407
P577
1986-08-01T00:00:00Z